Preprint Article Version 1 This version is not peer-reviewed

The Influence of Initial Immunosuppression on the Kinetics of Humoral Response after SARS-CoV-2 Vaccination in Patients Undergoing Kidney Transplantation

Version 1 : Received: 9 September 2024 / Approved: 9 September 2024 / Online: 10 September 2024 (07:28:47 CEST)

How to cite: Foresto, R. D.; Souza, R. M.; dos Anjos, G. R.; Nakamura, M. R.; Goulart, H. D. S.; da Silva, R. S.; França, D. P.; Marques, E. F.; Lucena, E. F.; Cristelli, M. P.; Tedesco-Silva, H.; Requião-Moura, L.; Pestana, J. M. The Influence of Initial Immunosuppression on the Kinetics of Humoral Response after SARS-CoV-2 Vaccination in Patients Undergoing Kidney Transplantation. Preprints 2024, 2024090728. https://doi.org/10.20944/preprints202409.0728.v1 Foresto, R. D.; Souza, R. M.; dos Anjos, G. R.; Nakamura, M. R.; Goulart, H. D. S.; da Silva, R. S.; França, D. P.; Marques, E. F.; Lucena, E. F.; Cristelli, M. P.; Tedesco-Silva, H.; Requião-Moura, L.; Pestana, J. M. The Influence of Initial Immunosuppression on the Kinetics of Humoral Response after SARS-CoV-2 Vaccination in Patients Undergoing Kidney Transplantation. Preprints 2024, 2024090728. https://doi.org/10.20944/preprints202409.0728.v1

Abstract

The effect of initial immunosuppressive therapy on the kinetics of the SARS-CoV-2 vaccine-induced humoral response is unknown. Here, we compared the kinetics of SARS-CoV-2 vaccine-induced humoral response in chronic kidney disease patients undergoing kidney transplantation (KTRs) and compared to patients remaining on dialysis during the Omicron circulation. This prospective, non-randomized, real-world study included 113 KTRs and 108 patients on dialysis. Those with previous COVID-19 or negative IgG at screening were excluded. Blood samples were collected to assess SARS-CoV-2 IgG titers and neutralizing antibodies at months (M) 1, 3, 6, and 12. Seroreversion occurred in 1 KTR and in 3 patients on dialysis. KTRs had lower IgG titers over time (M1: 10,809.3±12,621.7 vs. 15,267.8±16,096.2 IU/mL; M3: 12,215.5±12,885.8 vs. 15,016.2±15,346.1 IU/mL; M6: 12,540.4±13,010.7 vs. 18,503.5±14,581.0 IU/mL; p=0.005), but Neutralizing antibodies were similar (M1: 94.0 vs. 90.3%; M3: 92.9 vs. 90.5%; M6: 99.0 vs. 95.5%; M12: 98.9 vs. 97.5%; p=0.812). During follow-up, KTRs received more vaccine (141 vs. 73; p<0,001) and had more COVID-19 (32.7% vs. 14.8%; p=0.002). Compared to patients on dialysis, KTRs had lower SARS-CoV-2 IgG titers and similar rates of seroreversion and neutralizing antibodies over time. Although KTRs received more boosters, they had a higher incidence of COVID-19.

Keywords

COVID-19; SARS-CoV-2; vaccine; kidney transplant; dialysis; immunosuppression

Subject

Medicine and Pharmacology, Transplantation

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.